PROPOSED AMENDMENTS TO THE CLAIMS IN APPLICATION 10/642,440

A listing of the claims presented in this patent application appears below. This listing replaces all prior versions and listing of claims in this patent application.

Claim 1 (Currently Amended): A compound having a structure of ~~including resolved enantiomers, solvates, diastereomers and pharmaceutically acceptable salts thereof, said compound comprising~~ Formula I:



(I),

or resolved enantiomers, diastereomers or pharmaceutically acceptable salts thereof; wherein

an A group is bonded to at least one of the carbons at the 5, 6, 7 or 8 position of the bicyclic ring, and the ring is substituted by up to three independent R^3 groups;

X is N;

R^1 is a substituted or unsubstituted[[,]] ~~monocyclic or bicyclic, aryl moiety~~ phenyl;

R^2 is H or a substituted or unsubstituted C_{1-8} alkyl;

R^3 is hydrogen, ~~halogen, cyano, nitro~~[[,]] C_1-C_{10} alkyl, C_2-C_{10} alkenyl, C_2-C_{10} alkynyl, C_3-C_{10} cycloalkyl, C_3-C_{10} cycloalkylalkyl, aryl, arylalkyl, ~~heteroaryl, heteroarylalkyl, heterocyclyl, heterocyclylalkyl, $NR^4SO_2R^5$, $SO_2NR^6R^4$, $C(O)R^6$, $C(O)OR^6$~~[[,]] $-OC(O)R^6$, ~~$NR^4C(O)OR^5$, $NR^4C(O)R^6$, $C(O)NR^4R^6$~~[[,]] $-NR^4R^6$, ~~$NR^4C(O)NR^4R^6$~~[[,]] or $-OR^6$, ~~$S(O)R^5$, SO_2R^5~~[[,]] where each of the above alkyl, alkenyl, alkynyl, cycloalkyl[[,]] and aryl[[,]] ~~heteroaryl and heterocyclyl~~ portion of R^3 is optionally substituted with one to five groups independently selected from oxo, ~~halogen, cyano, nitro, trifluoromethyl, difluoromethoxy, trifluoromethoxy, azido, $NR^4SO_2R^5$, $SO_2NR^6R^4$, $C(O)R^6$, $C(O)OR^6$~~[[,]] $-OC(O)R^6$, ~~$NR^4C(O)OR^5$, $NR^4C(O)CR^6$, $C(O)NR^4R^6$~~[[,]] $-NR^4R^6$, ~~$NR^4C(O)NR^4R^6$, $NR^4C(NCN)NR^4R^6$~~[[,]] $-OR^6$, ~~$S(O)R^5$, SO_2R^5~~[[,]] aryl[[,]] and arylalkyl, ~~heteroaryl, heteroarylalkyl, heterocyclyl, and heterocyclylalkyl~~;

A is $-(U)_nZ$, where

n is 0;

Application 10/642,440

Z is



;

where W and V are selected independently from CR^7R^8, CR^8R^9, O, [[-S]] S, SO, SO_2, provided

if W is O, [[-S]] S, SO, SO_2, then V is CR^8R^9, and provided that R^6 directly bonded to Z is not H;

Z includes one or more R^8 or R^9 groups, wherein said R^8 and R^9 groups may be bonded to the same or different atoms;

R^4 is H or C_{1-6} alkyl;

R^5 is trifluoromethyl, C_1-C_{10} alkyl, C_3-C_{10} cycloalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, heterocyclyl, heterocyclylalkyl, where each alkyl, cycloalkyl, aryl, heteroaryl, heterocyclyl and heterocyclylalkyl is optionally substituted with one to five groups independently selected from oxo, halogen, cyano, nitro, OR^6, NR^4R^6, trifluoromethyl, difluoromethoxy, trifluoromethoxy, azido, aryl, heteroaryl, arylalkyl, heteroarylalkyl, heterocyclyl, and heterocyclylalkyl;

R^6, R^8 and R^9 are independently selected from hydrogen, trifluoromethyl, C_1-C_{10} alkyl, $(CH_2)_{0-4}C_3$-C_{10} cycloalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, heterocyclyl, heterocyclylalkyl, where each alkyl, cycloalkyl, aryl, heteroaryl and heterocyclyl is optionally substituted with one to five groups independently selected from oxo, halogen, cyano, nitro, OR^6, NR^6R^8, trifluoromethyl, difluoromethoxy, trifluoromethoxy, azido, aryl, heteroaryl, arylalkyl, heteroarylalkyl, heterocyclyl, and heterocyclylalkyl;

R^7 is hydrogen, halogen, cyano, nitro, C_1-C_{10} alkyl, C_2-C_{10} alkenyl, C_2-C_{10} alkynyl, C_3-C_{10} cycloalkyl, C_3-C_{10} cycloalkylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, heterocyclyl, heterocyclylalkyl, $-NR^4SO_2R^5$ $-SO_2NR^6R^4$, $-C(O)R^6$, $-C(O)OR^6$, $-OC(O)R^6$, $-NR^4C(O)OR^5$, $-NR^4C(O)R^6$, $-C(O)NR^4R^6$, $-NR^4R^6$, $-NR^4C(O)NR^4R^6$, $-OR^6$, $-S(O)R^5$, $-SO_2R^5$, where each of the above alkyl, alkenyl, alkynyl, cycloalkyl, aryl, heteroaryl and heterocyclyl portion of R^3 is

optionally substituted with one to five groups independently selected from oxo, halogen, cyano, nitro, trifluoromethyl, difluoromethoxy, trifluoromethoxy, azido, $-NR^4SO_2R^5$, $-SO_2NR^6R^4$, $-C(O)R^6$, $-C(O)OR^6$, $-OC(O)R^6$, $-NR^4C(O)OR^5$, $-NR^4C(O)CR^6$, $-C(O)NR^4R^6$, $-NR^4R^6$, $-NR^4C(O)NR^4R^6$, $-NR^4C(NCN)NR^4R^6$, $-OR^6$, $-S(O)R^5$, $-SO_2R^5$, aryl, arylalkyl, heteroaryl, heteroarylalkyl, heterocyclyl, and heterocyclylalkyl;

an R^4 group and an R^6 group may be independently joined to complete a 3 to 10 membered cyclic ring optionally containing additional heteroatoms selected from the group consisting of O, S, SO, SO_2 and NR^6 where each ring carbon may be optionally substituted with one to three groups independently selected from halogen, cyano, nitro, trifluoromethyl, difluoromethoxy, trifluoromethoxy, azido, aryl, OR^8, NR^6R^8, heteroaryl, arylalkyl, heteroarylalkyl, heterocyclyl, and heterocyclylalkyl; provided said ring does not contain two adjacent O or two adjacent S atoms;

an R^6 group and an R^8 group may be independently joined to complete a 3 to 10 membered cyclic ring optionally containing additional heteroatoms selected from the group consisting of O, S, SO, SO_2 and NR^6 where each ring carbon may be optionally substituted with one to three groups independently selected from halogen, cyano, nitro, trifluoromethyl, difluoromethoxy, trifluoromethoxy, azido, aryl, OR^8, NR^6R^8, heteroaryl, arylalkyl, heteroarylalkyl, heterocyclyl, and heterocyclylalkyl; provided said ring does not contain two adjacent O or two adjacent S atoms;

an R^7 group and an R^8 group may be independently joined to complete a 3 to 10 membered cyclic ring optionally containing additional heteroatoms selected from the group consisting of O, S, SO, SO_2 and NR^6 where each ring carbon may be optionally substituted with one to three groups independently selected from halogen, cyano, nitro, trifluoromethyl, difluoromethoxy, trifluoromethoxy, azido, aryl, OR^8, NR^6R^8, heteroaryl, arylalkyl, heteroarylalkyl, heterocyclyl, and heterocyclylalkyl; provided said ring does not contain two adjacent O or two adjacent S atoms; and

an R^8 group and an R^9 group may be independently joined to complete a 3 to 10 membered cyclic ring optionally containing additional heteroatoms selected from the group consisting of O, S, SO, SO_2 and NR^6 where each ring carbon may be optionally substituted with

one to three groups independently selected from halogen, cyano, nitro, trifluoromethyl, difluoromethoxy, trifluoromethoxy, azido, aryl, OR^8, NR^6R^8, heteroaryl, arylalkyl, heteroarylalkyl, heterocyclyl, and heterocyclylalkyl; provided said ring does not contain two adjacent O or two adjacent S atoms.

Claim 2: (Canceled).

Claim 3 (Currently Amended): The compound of claim 1, wherein [[a]] the A group is bonded to at least one of the carbons at the 6 or 7 position of the bicyclic ring.

Claim 4 (Previously Amended): The compound of claim 1, wherein R^2 is hydrogen, and R^3 is hydrogen or OR^6.

Claim 5 (Previously Amended): The compound of claim 3, wherein R^3 is hydrogen or OR^6.

Claim 6 (Original Claim): The compound of claim 1, wherein R^2 is hydrogen.

Claim 7 (Previously Amended): The compound of claim 1, wherein Z is



;

and W is O.

Claim 8 (Previously Amended): The compound of claim 5, wherein Z is



;

and W is O.

Claim 9 (Original Claim): The compound of claim 1, wherein the R^4 group and the R^6 group are independently joined to complete a 3 to 10 membered cyclic ring optionally containing additional heteroatoms selected from the group consisting of O, S, SO, SO_2 and NR^6 where each ring carbon may be optionally substituted with one to three groups independently selected from halogen, cyano, nitro, trifluoromethyl, difluoromethoxy, trifluoromethoxy, azido, aryl, OR^8, NR^6R^8, heteroaryl, arylalkyl, heteroarylalkyl, heterocyclyl, and heterocyclylalkyl; provided said ring does not contain two adjacent O or two adjacent S atoms.

Claim 10 (Original Claim): The compound of claim 1, wherein the R^6 group and the R^8 group are independently joined to complete a 3 to 10 membered cyclic ring optionally containing additional heteroatoms selected from the group consisting of O, S, SO, SO_2 and NR^6 where each ring carbon may be optionally substituted with one to three groups independently selected from halogen, cyano, nitro, trifluoromethyl, difluoromethoxy, trifluoromethoxy, azido, aryl, OR^8, NR^6R^8, heteroaryl, arylalkyl, heteroarylalkyl, heterocyclyl, and heterocyclylalkyl; provided said ring does not contain two adjacent O or two adjacent S atoms.

Claim 11 (Previously Amended): The compound of claim 1, wherein the R^7 group and the R^8 group are independently joined to complete a 3 to 10 membered cyclic ring optionally containing additional heteroatoms selected from the group consisting of O, S, SO, SO_2 and NR^6 where each ring carbon may be optionally substituted with one to three groups independently selected from halogen, cyano, nitro, trifluoromethyl, difluoromethoxy, trifluoromethoxy, azido,

aryl, OR^8, NR^6R^8, heteroaryl, arylalkyl, heteroarylalkyl, heterocyclyl, and heterocyclylalkyl; provided said ring does not contain two adjacent O or two adjacent S atoms.

Claim 12 (Original Claim): The compound of claim 1, wherein the R^8 group and the R^9 group are independently joined to complete a 3 to 10 membered cyclic ring optionally containing additional heteroatoms selected from the group consisting of O, S, SO, SO_2 and NR^6 where each ring carbon may be optionally substituted with one to three groups independently selected from halogen, cyano, nitro, trifluoromethyl, difluoromethoxy, trifluoromethoxy, azido, aryl, OR^8, NR^6R^8, heteroaryl, arylalkyl, heteroarylalkyl, heterocyclyl, and heterocyclylalkyl; provided said ring does not contain two adjacent O or two adjacent S atoms.

Claim 13 (Currently Amended): A method of treating ~~hyperproliferative diseases~~ inflammation and cancer of the colon, ovary, bladder, breast, stomach, esophagus, lung, uterus and prostate in a mammal comprising administering a therapeutically effective amount of the compound defined in claim 1 to said mammal.

Claim 14 (Currently Amended): A method of treating ~~hyperproliferative diseases~~ inflammation and cancer of the colon, ovary, bladder, breast, stomach, esophagus, lung, uterus and prostate in a mammal comprising administering a therapeutically effective amount of the compound defined in claim 2 to said mammal.

Claim 15 (Currently Amended): A method of treating ~~hyperproliferative diseases~~ inflammation and cancer of the colon, ovary, bladder, breast, stomach, esophagus, lung, uterus and prostate in a mammal comprising administering a therapeutically effective amount of the compound defined in claim 3 to said mammal.

Claim 16 (Currently Amended): A method of treating ~~hyperproliferative diseases~~ inflammation and cancer of the colon, ovary, bladder, breast, stomach, esophagus, lung, uterus

and prostate in a mammal comprising administering a therapeutically effective amount of the compound defined in claim 4 to said mammal.

Claim 17 (Currently Amended): A method of treating ~~hyperproliferative diseases~~ inflammation and cancer of the colon, ovary, bladder, breast, stomach, esophagus, lung, uterus and prostate in a mammal comprising administering a therapeutically effective amount of the compound defined in claim 5 to said mammal.

Claim 18 (Currently Amended): A method of treating ~~hyperproliferative diseases~~ inflammation and cancer of the colon, ovary, bladder, breast, stomach, esophagus, lung, uterus and prostate in a mammal comprising administering a therapeutically effective amount of the compound defined in claim 6 to said mammal.

Claim 19 (Currently Amended): A method of treating ~~hyperproliferative diseases~~ inflammation and cancer of the colon, ovary, bladder, breast, stomach, esophagus, lung, uterus and prostate in a mammal comprising administering a therapeutically effective amount of the compound defined in claim 7 to said mammal.

Claim 20 (Currently Amended): A method of treating ~~hyperproliferative diseases~~ inflammation and cancer of the colon, ovary, bladder, breast, stomach, esophagus, lung, uterus and prostate in a mammal comprising administering a therapeutically effective amount of the compound defined in claim 8 to said mammal.

Claim 21 (Currently Amended): A method of treating ~~hyperproliferative diseases~~ inflammation and cancer of the colon, ovary, bladder, breast, stomach, esophagus, lung, uterus and prostate in a mammal comprising administering a therapeutically effective amount of the compound defined in claim 9 to said mammal.

Claim 22 (Currently Amended): A method of treating ~~hyperproliferative diseases~~ inflammation and cancer of the colon, ovary, bladder, breast, stomach, esophagus, lung, uterus and prostate in a mammal comprising administering a therapeutically effective amount of the compound defined in claim 10 to said mammal.

Claim 23 (Currently Amended): A method of treating ~~hyperproliferative diseases~~ inflammation and cancer of the colon, ovary, bladder, breast, stomach, esophagus, lung, uterus and prostate in a mammal comprising administering a therapeutically effective amount of the compound defined in claim 11 to said mammal.

Claim 24 (Currently Amended): A method of treating ~~hyperproliferative diseases~~ inflammation and cancer of the colon, ovary, bladder, breast, stomach, esophagus, lung, uterus and prostate in a mammal comprising administering a therapeutically effective amount of the compound defined in claim 12 to said mammal.

Claim 25 (Previously Presented): The compound of claim 1, wherein R^1 is selected from the structures:













and 

Claim 26 (Previously Presented): The compound of claim 7, wherein R^6 is an optionally substituted alkyl or cycloalkyl.

Claim 27 (Previously Presented): The compound of claim 26, wherein R^6 is methyl, ethyl, CH_2CF_3, CH_2CH_2OH, or cyclopropyl.

Claim 28 (Previously Presented): The compound of claim 26, wherein R^8 and R^9 are independently an optionally substituted alkyl.

Claim 29 (Previously Presented): The compound of claim 28, wherein R^8 and R^9 are independently CH_2OH, CH_2NMe_2 or CH_2O-t-butyl.

Claim 30 (Previously Presented): The compound of claim 26, wherein R^8 and R^9 together with the atoms to which they are attached form an optionally substituted heterocyclic ring.

Claim 31 (Previously Amended): The compound of claim 7, wherein Z is selected from the structures:

















Claim 32 (Previously Presented): The compound of claim 1, wherein Z is



Claim 33 (Previously Presented): The compound of claim 32, wherein R^6 is an optionally substituted alkyl.

Claim 34 (Previously Amended): The compound of claim 33, wherein R^6 is methyl.

Claim 35 (Previously Presented): The compound of claim 34, wherein Z is



Claim 36 (Previously Amended): The compound of claim 1, selected from:

N4-[3-Chloro-4-(3-fluorobenzyloxy)-phenyl]-N6-(3-methyl-oxazolidin-2-ylidene)-quinazoline-4,6-diamine;

N-4-[3-Chloro-4-(3-fluorobenzyloxy)-phenyl]-N6-(3-ethyl-oxazolidin-2-ylidene)-quinazoline-4,6-diamine;

(2-{4-[3-Chloro-4-(3-fluorobenzyloxy)-phenylamino]-quinazolin-6-ylimino}-3-methyl-oxazolidin-5-yl)-methanol;

2-(2-{4-[3-Chloro-4-(3-fluorobenzyloxy)-phenylamino]-quinazolin-6-ylimino}-oxazolidin-3-yl)-ethanol;

N-4-[3-Chloro-4-(3-fluorobenzyloxy)-phenyl]-N6-(4-dimethylaminomethyl-3-methyl-oxazolidin-2-ylidene)-quinazoline-4,6-diamine;

(*S*)-N6-(4-tert-Butoxymethyl-3-methyl-oxazolidin-2-ylidene)-N4-[3-chloro-4-(3-fluoro-phenoxymethyl)-phenyl]-quinazoline-4,6-diamine;

(*S*)-(2-{4-[3-Chloro-4-(3-fluorophenoxymethyl)-phenylamino]-quinazolin-6-ylimino}-3-methyl-oxazolidin-4-yl)-methanol;

(2-{4-[3-Chloro-4-(3-fluorophenoxymethyl)-phenylamino]-quinazolin-6-ylimino}-3-methyl-oxazolidin-5-yl)-methanol;

{3-Methyl-2-[4-(3-methyl-4-phenoxyphenylamino)-quinazolin-6-ylimino]-oxazolidin-5-yl}-methanol;

(2-{4-[3-Chloro-4-(6-methylpyridin-3-yloxy)-phenylamino]-quinazolin-6-ylimino}-3-methyl-oxazolidin-5-yl)-methanol;

N4-(4-Benzenesulfonylphenyl)-N6-(3-methyloxazolidin-2-ylidene)-quinazoline-4,6-diamine;

{2-[4-(4-Benzenesulfonylphenylamino)-quinazolin-6-ylimino]-3-methyl-oxazolidin-5-yl}-methanol;

N4-(4-Benzenesulfonylphenyl)-N6-(3-cyclopropyloxazolidin-2-ylidene)-quinazoline-4,6-diamine;

N6-(Dimethylhexahydropyrrolo[3,4-d]oxazol-2-ylidene)-N4-(3-methyl-4-phenoxyphenyl)-quinazoline-4,6-diamine;

N4-[3-Chloro-4-(thiazol-2-ylmethoxy)-phenyl]-N6-(3-methyloxazolidin-2-ylidene)-quinazoline-4,6-diamine;

N4-[3-Chloro-4-(pyridin-2-ylmethoxy)-phenyl]-N6-(dimethyl-3-oxa-1,8-diaza-spiro[4.5]dec-2-ylidene)-quinazoline-4,6-diamine;

[2-{4-[3-Chloro-4-(3-fluorobenzyloxy)-phenylamino]-quinazolin-6-ylimino}-3-(2,2,2-trifluoroethyl)-oxazolidin-5-yl]-methanol; and

N4-[3-Chloro-4-(3-fluorobenzyloxy)-phenyl]-N6-(1-methylpyrrolidin-2-ylidene)-quinazoline-4,6-diamine.

Application 10/642,440

Claim 37 (Currently Amended): A compound ~~including resolved enantiomers, diastereomers and pharmaceutically acceptable salts thereof, said compound comprising~~ having a structure of Formula I:



(I),

or resolved enantiomers, diastereomers or pharmaceutically acceptable salts thereof,

wherein

X is N;

R^1 is selected from the structures:















and ;

R^2 is hydrogen or a substituted or unsubstituted C_{1-8} alkyl;

R^3 is hydrogen, ~~halogen, cyano, nitro~~[[,]] C_1-C_{10} alkyl, C_2-C_{10} alkenyl, C_2-C_{10} alkynyl, C_3-C_{10} cycloalkyl, C_3-C_{10} cycloalkylalkyl, aryl, arylalkyl, ~~heteroaryl, heteroarylalkyl, heterocyclyl, heterocyclylalkyl, $-NR^4SO_2R^5$, $-SO_2NR^6R^4$, $-C(O)R^6$, $-C(O)OR^6$~~[[,]] $-OC(O)R^6$, ~~$-NR^4C(O)OR^5$, $-NR^4C(O)R^6$, $-C(O)NR^4R^6$~~[[,]] $-NR^4R^6$, ~~$-NR^4C(O)NR^4R^6$~~[[,]] or $-OR^6$, ~~$-S(O)R^5$,~~

~~SO_2R^5~~[[,]] where each of the above alkyl, alkenyl, alkynyl, cycloalkyl[[,]] and aryl[[,]] ~~heteroaryl and heterocyclyl~~ portion of R^3 is optionally substituted with one to five groups independently selected from oxo, ~~halogen, cyano, nitro, trifluoromethyl, difluoromethoxy, trifluoromethoxy, azido, $NR^4SO_2R^5$, $SO_2NR^6R^4$, $C(O)R^6$, $C(O)OR^6$~~[[,]] $-OC(O)R^6$, ~~$NR^4C(O)OR^5$, $NR^4C(O)CR^6$, $C(O)NR^4R^6$~~[[,]] $-NR^4R^6$, ~~$NR^4C(O)NR^4R^6$, $NR^4C(NCN)NR^4R^6$~~[[,]] $-OR^6$, ~~$S(O)R^5$, SO_2R^5~~[[,]] aryl[[,]] and arylalkyl[[,]] ~~heteroaryl, heteroarylalkyl, heterocyclyl, and heterocyclylalkyl~~;

A is $-(U)_nZ$, where

n is 0; and

Z is selected from the following structures:














Claim 38: (Canceled).

Claim 39 (Currently Amended): The compound of claim 37, wherein R^2 is hydrogen.

Claim 40 (Currently Amended): The compound of claim 37, wherein R^3 is hydrogen.